

# Alzheimer's Disease: Addressing the Underlying Mechanisms of Preclinical Disease and Mild Cognitive Impairment

## PODCAST

### KEY REFERENCES

1. Alzheimer's Association. 2021 Alzheimer's disease facts and figures. *Alzheimers Dement*. 2021;17(3):327-406. doi:10.1002/alz.12328
2. Dong X, Chen R, Simon MA. Elder abuse and dementia: a review of the research and health policy. *Health Aff (Millwood)*. 2014;33(4):642-649. doi:10.1377/hlthaff.2013.1261
3. Rubin L, Ingram LA, Resciniti NV, et al. Genetic risk factors for Alzheimer's disease in racial/ethnic minority populations in the U.S.: a scoping review. *Front Public Health*. 2021;9:784958. doi:10.3389/fpubh.2021.784958
4. Lanoiselée HM, Nicolas G, Wallon D, et al. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: a genetic screening study of familial and sporadic cases. *PLoS Med*. 2017;14(3):e1002270. doi:10.1371/journal.pmed.1002270
5. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet*. 2020;396(10248):413-446. doi:10.1016/S0140-6736(20)30367-6
6. Vickrey BG, Mittman BS, Connor KI, et al. The effect of a disease management intervention on quality and outcomes of dementia care: a randomized, controlled trial. *Ann Intern Med*. 2006;145(10):713-726. doi:10.7326/0003-4819-145-10-200611210-00004
7. Rosenberg A, Ngandu T, Rusanen M, et al. Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: the FINGER trial. *Alzheimers Dement*. 2018;14(3):263-270. doi:10.1016/j.jalz.2017.09.006
8. Mahase E. Aducanumab: European agency rejects Alzheimer's drug over efficacy and safety concerns. *BMJ*. 2021;375:n3127. doi:10.1136/bmj.n3127
9. Tampi RR, Forester BP, Agronin M. Aducanumab: evidence from clinical trial data and controversies. *Drugs Context*. 2021;10:2021-7-3. doi:10.7573/dic.2021-7-3
10. García-Morales V, González-Acedo A, Melguizo-Rodríguez L, et al. current understanding of the physiopathology, diagnosis and therapeutic approach to Alzheimer's disease. *Biomedicines*. 2021;9(12):1910. doi:10.3390/biomedicines9121910
11. Safieh M, Korczyn AD, Michaelson DM. ApoE4: an emerging therapeutic target for Alzheimer's disease. *BMC Med*. 2019;17(1):64. doi:10.1186/s12916-019-1299-4
12. Graff-Radford NR, Crook JE, Lucas J, et al. Association of low plasma Aβ<sub>42</sub>/Aβ<sub>40</sub> ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease [published correction appears in *Arch Neurol*. 2007;64(9):1246]. *Arch Neurol*. 2007;64(3):354-362. doi:10.1001/archneur.64.3.354
13. Zetterberg H, Bendlin BB. Biomarkers for Alzheimer's disease—preparing for a new era of disease-modifying therapies. *Mol Psychiatry*. 2021;26(1):296-308. doi:10.1038/s41380-020-0721-9